Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 12/20 | 0.60 |
| ▸ | HTR2C | P28335 | 7/20 | 0.43 |
| ▸ | HTR2B | P41595 | 7/20 | 0.43 |
| ▸ | HTR2A | P28223 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7061272 | 0.89 | KDM1A (0.69) | KDM1AHTR2CHTR2BHTR2A | |
| SCHEMBL6906205 | 0.85 | KDM1A (0.54) | KDM1AHTR2CHTR2BHTR2A | |
| SCHEMBL7526567 | 0.85 | KDM1A (0.57) | KDM1AHTR2CHTR2BHTR2A | |
| SCHEMBL7526575 | 0.85 | KDM1A (0.57) | KDM1AHTR2CHTR2BHTR2A | |
| SCHEMBL7661595 | 0.84 | KDM1A (0.46) | KDM1AHTR2CHTR2BHTR2A | |
| SCHEMBL24240291 | 0.73 | L3MBTL1 (0.47) | KDM1A | |
| SCHEMBL17527769 | 0.73 | L3MBTL1 (0.48) | KDM1A | |
| SCHEMBL17962677 | 0.73 | HTR2C (0.77) | HTR2CHTR2BHTR2A | |
| SCHEMBL4405598 | 0.72 | ALDH1A1 (0.45) | KDM1A | |
| SCHEMBL6906698 | 0.71 | KDM1A (0.56) | KDM1AHTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116418-A1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 2004-06-17 | — | — | US | disclosed |
| US-20020132794-A1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB | 2002-09-19 | — | — | US | disclosed |
| US-6376492-B1 | GUANIDINE DERIVATIVES | MEDIVIR AB (SE) | 2002-04-23 | — | — | US | disclosed |
| US-5849769-A | N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection | MEDIVIR AB (SE) | 1998-12-15 | — | — | US | disclosed |
| EP-0706514-B1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1998-11-18 | — | — | EP | disclosed |
| EP-0706514-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995006034-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1995-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132794-A1 | Compounds and methods for inhibition of HIV and related viruses | POLRMT, POLM, POLR1E | KDM1A 1796/4885HTR2C 4429/4885HTR2B 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.